Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine

Current HIV Research

Volumn 7, Issue 5, 2009, Pages 526-532

  Rodríguez Arrondo, Francisco ^a   Aguirrebengoa, Koldo ^b   Portu, Joseba ^c   Muñoz, Josefa ^d   García, Ma Asunción ^e   Goikoetxea, Josune ^b   Martínez, Eduardo ^e   Iribarren, Jose A ^a   Perez Alvarez, Nuria ^f,g   Negredo, Eugenia ^g   Clotet, Bonaventura ^g  

^a HOSPITAL DONOSTIA   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL TXAGORRITXU   (Spain)

^d HOSPITAL DE BASURTO   (Spain)

^e HOSPITAL DE GALDAKAO   (Spain)

^f UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Antiretroviral therapy; Cardiovascular risk; Dislypidemia; HDL cholesterol; Hepatitis C; HIV 1 infection; Hyperlipidemias; Nevirapine

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEPATITIS C ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; DIARRHEA; DISTRESS SYNDROME; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEPATITIS C; HIGH RISK PATIENT; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; INTRAVENOUS DRUG ABUSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MOUTH ULCER; NAUSEA AND VOMITING; NEPHROLITHIASIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70350719525     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209789346246     Document Type: Article

References (25)

1. Lundgren JD, Neuhaus J, Babiker A, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV infected patients. AIDS 2008; 22: F17-F24.
2. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356(9239): 1423-1430
3. Dube M, Fenton M. Lipid abnormalities. Clin Infect Dis 2003; 36(Suppl 2): S79-S83.
4. Fisac C, Fumero E, Crespo M, et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005; 19(9): 917-925 (Pubitemid 40834934)
5. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39(4): 395-400.
6. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16(10): 1383-1389 (Pubitemid 34722070)
7. Bonjoch A, Paredes R, Domingo P, et al. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2006; 22(4): 321-329
8. Sankatsing R, Franssen R, Hassink E, et al. Nevirapine Increases High Density Lipoprotein-cholesterol by Stimulation of Apolipoprotein A-I Synthesis. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention Sydney, Australia, July 22-25 2007. Abstract: WEPEB120LB.
9. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral Treatment of Adult HIV Infection: 2008 Recommendations of the International AIDS Society-USA Panel. JAMA 2008; 300(5): 555-570
10. van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003; 17(7): 987-999 (Pubitemid 36549710)
11. Podzamczer D, Ferrer E, Consiglio E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 2002; 7(2): 81-90. (Pubitemid 36427149)
12. Coloma AG, Alvarez M, Roca-Cusachs A, Domingo P, Puig M. Prevalence of arterial hypertension and lipid profile in HIV patients. Med Clin (Barc) 2008; 131(18): 681-684
13. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIVinfected individuals. J Acquir Immune Defic Syndr 2003; 33(4): 506-512 (Pubitemid 36886080)
14. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000; 31(3): 787-797 (Pubitemid 32295503)
15. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42(9): 1325-1332
16. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intimamedia thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19(9): 927-933 (Pubitemid 40834935)
17. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109(13): 1603-1608 (Pubitemid 38451715)
18. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349(21): 1993-2003.
19. Lundgren J, Neuhaus J, Babiker A, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIVinfected patients enrolled in the SMART study. AIDS 2008 - XVII International AIDS Conference 2008. Abstract: THAB0305.
20. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360(9347): 1747-1748 (Pubitemid 35447907)
21. Madden E, Lee G, Kotler DP, et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. AIDS 2008; 22(6): 707-715
22. Medrano J, Barreiro P, Tuma P, et al. Risk for immune-mediated liver reactions by nevirapine revisited. AIDS Rev 2008; 10(2): 110-115
23. De Lazzari E, Leon A, Arnaiz JA, et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts. HIV Med 2008; 9(4): 221-226
24. Ena J, Leach A, Nguyen P. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a metaanalysis of randomized controlled trials. HIV Med 2008; 9(9): 747-756
25. Reliquet V, Allavena C, François-Brunet C, et al. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study. HIV Med 2006; 7(7): 431-436 (Pubitemid 44269809)